Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
John E. Anderson, Vivian T. Thieu, Kristina S. Boye, Ryan T. Hietpas & Luis-Emilio Garcia-Perez. (2016) Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. Postgraduate Medicine 128:8, pages 810-821.
Read now
Read now
Articles from other publishers (17)
Kristina S. Boye, Jessica B. Jordan, Raleigh Malik & Louis S. Matza. (2023) Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States. Diabetes Therapy.
Crossref
Crossref
Julia Liaw, Meera Harhay, Soko Setoguchi, Tobias Gerhard & Chintan V. Dave. (2022) Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006–2020. Diabetes Care 45:10, pages 2316-2325.
Crossref
Crossref
Hae-Jin Ko, Jin-Wook Kim & Soo Lim. (2022) Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting. Journal of Obesity & Metabolic Syndrome 31:3, pages 254-262.
Crossref
Crossref
E. Soubry, C. Mathieu, G. Vandistel & A. Mertens. (2022) Orale semaglutide: een nieuwe en eerste orale GLP1-receptoragonist. Tijdschrift voor Geneeskunde.
Crossref
Crossref
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Hirotaka Ono, Tadamichi Kawano, Yuji Yoshida, Tomomi Okubo, Korenobu Hayama, Ai Nakagawa‐Iwashita, Norio Itokawa, Chisa Kondo, Mototsugu Nagao & Katsuhiko Iwakiri. (2022) Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. JGH Open 6:7, pages 503-511.
Crossref
Crossref
Sanjay Kalra & Nitin Kapoor. (2022) Oral Semaglutide: Dosage in Special Situations. Diabetes Therapy 13:6, pages 1133-1137.
Crossref
Crossref
Kamran Qureshy, Andreas Ross Kirk, Michael Lyng Wolden, Amir Abbas Mohseni Zonoozi & Aiden Liu. (2022) A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada. Cardiovascular Endocrinology & Metabolism 11:2.
Crossref
Crossref
Elizabeth Holmes‐Truscott, Jasmine Schipp, Trisha Dunning, John Furler, Virginia Hagger, Edith E. Holloway, Jo‐Anne Manski‐Nankervis, Jonathan E. Shaw, Timothy Skinner & Jane Speight. (2021) ‘For me, it didn’t seem as drastic a step as being controlled by insulin’: A qualitative investigation of expectations and experiences of non‐insulin injectable therapy among adults with type 2 diabetes. Diabetic Medicine 39:2.
Crossref
Crossref
Monica Agarwal & Karl Nadolsky. (2022) Attitudes, Perceptions, and Practices Among Endocrinologists Managing Obesity. Endocrine Practice 28:2, pages 179-184.
Crossref
Crossref
Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Debbie Hicks, Pam Brown, Zaheer Yousef, Umesh Dashora, Adie Viljoen, Hannah Beba & W. David Strain. (2022) Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Therapy 13:2, pages 225-240.
Crossref
Crossref
Baptist Gallwitz & Francesco Giorgino. (2021) Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Frontiers in Endocrinology 12.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas & Luis‐Emilio García‐Pérez. (2019) Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism 22:3, pages 355-364.
Crossref
Crossref
Arsalan Hamid, Muthiah Vaduganathan, Adebamike A. Oshunbade, Krishna K. Ayyalasomayajula, Andreas P. Kalogeropoulos, Lillian F. Lien, Tariq Shafi, Michael E. Hall & Javed Butler. (2020) Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. Journal of Cardiovascular Pharmacology 76:3, pages 313-320.
Crossref
Crossref
K. Winkley, R. Upsher, W. H. Polonsky & E. Holmes‐Truscott. (2019) Psychosocial aspects and contributions of behavioural science to medication‐taking for adults with type 2 diabetes. Diabetic Medicine.
Crossref
Crossref
Kristina S. Boye, Dara Stein, Louis S. Matza, Jessica Jordan, Ren Yu, Kirsi Norrbacka, Syed Wasi Hassan & Luis-Emilio García-Pérez. (2019) Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK. Drugs in R&D 19:2, pages 213-225.
Crossref
Crossref
Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta & Jesús Reviriego. (2018) A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes Therapy 10:1, pages 5-19.
Crossref
Crossref
Antonios Douros, Kristian B. Filion, Hui Yin, Oriana Hoi Yu, Mahyar Etminan, Jacob A. Udell & Laurent Azoulay. (2018) Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Diabetes Care 41:11, pages 2330-2338.
Crossref
Crossref